A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Inclusion Criteria Patients must have or be: * Healthy. * Negative ELISA for HIV. * Negative for Hepatitis B surface antigen. * Normal urine dipstick. * Normal history and physical exam. * Availability for follow-up for planned duration of the study (60 weeks). Risk Behavior: Required: * Lower or intermediate risk sexual behavior as defined by AVEG. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: * Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol. * Active syphilis. NOTE: If the serology is documented to be a false positive or due to a remote (\> 6 months) treated infection, the volunteer is eligible. * Active tuberculosis. NOTE: Volunteers with a positive PPD and a normal chest X-ray showing no evidence of TB and not requiring INH therapy are eligible. Patients with any of the following prior conditions are excluded: * History of immunodeficiency, chronic illness, malignancy or autoimmune disease. * History of anaphylaxis or other serious adverse reactions to vaccines. * History of inflammatory gastrointestinal disease, celiac disease or intestinal malignancy. * History of acute gastroenteritis within the past month or gastrointestinal surgery within the past 12 months. Prior Medication: Excluded: * History of use of immunosuppressive medication. * Live attenuated vaccines within 60 days of study. NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are not exclusionary but should be given at least 2 weeks away from HIV immunizations. * Use of experimental agents within 30 days prior to study. * Receipt of blood products or immunoglobulin in the past 6 months. * Prior receipt of HIV vaccines or a placebo recipient in an HIV vaccine trial. Risk Behavior: Excluded: * Subjects with identifiable higher risk behavior for HIV infection as determined by screening questionnaire designed to identify risk factors for HIV infection. * History of injection drug use within the last 12 months to enrollment. * Higher risk sexual behavior as defined by AVEG.